Variant Summary
- Also known as
- LEU858ARG,RS121434568,L813R,LEU813ARG
- HGVS
- NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg
- Variant Type(s)
- missense_variant
- Evidence Items
- 37
Evidence Level Distribution
Level A: 2Level B: 13Level C: 3Level D: 19
Evidence Items
Showing CIViC evidence rows where gene = EGFR and variant = L858R.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Afatinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Dacomitinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib,Gefitinib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Afatinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Afatinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib,Gefitinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Lapatinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Dacomitinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Neratinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Canertinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Gefitinib | 3 |
| B | Prognostic | Supports | Better Outcome | Lung Non-small Cell Carcinoma | 3 | |
| D | Predictive | Supports | Sensitivity/Response | Cancer | Gefitinib,Multikinase Inhibitor AEE788,Erlotinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Cancer | Erlotinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib | 3 |
| C | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Crizotinib | 3 |
| D | Predictive | Does Not Support | Sensitivity/Response | Lung Adenocarcinoma | Cetuximab | 3 |
| D | Predictive | Supports | Sensitivity/Response | High Grade Glioma | Erlotinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Cancer | Erlotinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Afatinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Afatinib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Cancer | Erlotinib | 2 |
| B | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Erlotinib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Erlotinib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Lung Small Cell Carcinoma | Erlotinib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Osimertinib | 2 |
| B | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Gefitinib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Afatinib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Gefitinib | 1 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib | 1 |